Clinical Trial

A Study of Elenestinib in Healthy Adult Female Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
Protocol Amendment History 1 change
critical Trial completed 2026-04-21
Trial Details
NCT Number NCT07388511
Lead Sponsor Blueprint Medicines Corporation
Conditions Healthy Participants
Enrollment 20 participants
Start Date 2026-02-05
Primary Completion 2026-04-02 (estimated)
Study Completion 2026-04-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-20